Clinical Trial Update: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update of a tiragolumab plus atezolizumab combination for relapsed or refractory SMARCB1/SMARCA4-deficient tumors, spanning Phase 1 and Phase 2, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Teratoid Rhabdoid Tumor
• Chordoma
• Epithelioid Sarcoma
• Kidney Medullary Carcinoma
• Rhabdoid Tumor

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING